Studies show that people who exercise regularly while using a GLP-1 medication and continue exercising after stopping it tend to have less weight regain and are more likely to maintain their weight loss
In a 48-week clinical trial, higher doses consistently led to greater average weight loss: Weight loss by dose (48-week clinical trial) In this trial, at the highest dose (12 mg), people lost an average 24% of their starting weight on average
For an orthopedic surgeon, this is relevant because muscle mass is a primary driver of joint stability, injury prevention, and post-surgical recovery
It also influences insulin sensitivity and glucose metabolism, which are essential factors in weight management, especially for those with obesity-related health issues like type 2 diabetes
The 12mg weekly maintenance dose produced the greatest weight reduction (-24.2%) in Phase 2 trials
Every batch undergoes rigorous third-party testing to ensure purity levels meet the highest standards